DIA - Synterex, Inc. - Activity & Updates

Perk Name

Expiration Date(Optional)

Description

Terms & Condition

Custom Confirmation Message Redirect Website

Custom Confirmation Message

Notify of any claims

Perk Permissions

By default, anyone can see what you are offering but only members (and yourself, as the owner of the perk) can claim a perk. Use the following if you wish to adjust these permission settings.

View Permissions:

Who can see the Perk name and description

Everyone Members Only

Claim Permissions:

Who can claim a Perk

Everyone Members Only

Depending on your subscription plan, content can be Featured and distributed to the entire organization. Non-featured content is displayed on the activity stream and also sent to users who have Followed your listings.

Select the type of post you'd like to share

Featured

Unavailable

Non-Featured

;

Likes

Followers

About

Strategic Stakeholder Engagement

KOL Relationship Management

Regulatory

Maintenance & Renewals

Post-Approval Safety Reporting

Compliance

eCTD Publishing & Validation, Agency Meeting Support

Transparency & Disclosure

Clinical Transparency

Commercialization

Customer Engagement

Patient Engagement

Pharmacovigilance

Risk Management

Risk Evaluation & Minimization

Clinical Research

Study Operations & Management

Site Relationship Management

Clinical Reporting

Abstract & Poster Development

Technology & Operations

Data & Analytics

Artificial Intelligence

Employees & Contacts

26-75 Employees | 4 Contacts

Year Founded

2016

Headquarters

122 Rosemary Road, Dedham, MA 02026 7027, USA

Activity

Showing 9 records

C S

an Associate

22 days ago

added featured case study

Informed Consent Form of an IND Submission with AgileWriter™

A small biotech needed an informed consent form (ICF) for an IND submission, with limited lead time following agency feedback. The challenge was compounded by a lack of prior materials and an untested template.

Synterex’s Solution:
AgileWriter™ was pretrained using draft sources and updated incrementally as new protocol information became available. The model’s output was so robust it was also leveraged to produce a pregnant partner ICF for the same study.

C S

an Associate

22 days ago

added featured case study

Clinical Study Report and Narratives Initial Draft in Record Time with AgileWriter™

A medium-sized biotech faced a tight deadline: a comprehensive Clinical Study Report (CSR) shell and first draft were needed in just two weeks, compared to the industry norm of six or more. The project was further complicated by complex oncology study design and data in less-than-ideal formats.

Synterex’s Solution:
Leveraging AgileWriter™, Synterex trained an AI model in real time, mapping planned content to a CSR template and SDTM datasets. As new information arrived, the model was incrementally refined, with a medical writer overseeing the process to ensure quality and compliance.

C S

an Associate

1 month ago

added a social media link for

Synterex, Inc.

C S

an Associate

5 months ago

added a contact for

Synterex, Inc.

C S

an Associate

5 months ago

edited a contact for

Synterex, Inc.

E P

an Associate

1 year ago

added featured whitepaper

(White Paper) This One’s for the Children: Progress in Pediatric Drug Development in the United States

Prior to the FD&C Act, pharmaceutical companies were not required to provide proof of drug safety or a disclosure of all active ingredients. Since then, all new drugs undergo an intensive review process by the Food and Drug Administration (FDA), and ever-evolving guidance and regulations ensure that both new drugs and those with updated characteristics, such as dosing, delivery, and expanded indications, are safe and effective for the intended populations. A gap remains, however, for drug investigations including and targeted for children of varying ages.

Download and read now for more insights!

E P

an Associate

1 year ago

added featured whitepaper

(White Paper) The Road to Representation in Clinical Research

Innovative development of human drugs, biologics, and medical devices (medical products) and their quick advancement through the United States Food and Drug Administration (FDA) approval pipeline is necessary to improve the lives of patients. It is also imperative for sponsors to consider diversity when enrolling study participants throughout the clinical development pipeline to adequately represent the population of patients who have a disease or condition.

Download and read now for more insights!

C B

1 year ago

followed

Synterex, Inc.

Synterex, Inc.

Select type of event

About

Activity

All Users

All Activity

Most Recent

C S

Informed Consent Form of an IND Submission with AgileWriter™

C S

Clinical Study Report and Narratives Initial Draft in Record Time with AgileWriter™

C S

C S

C S

E P

(White Paper) This One’s for the Children: Progress in Pediatric Drug Development in the United States

E P

(White Paper) The Road to Representation in Clinical Research

C B

Invite Supplier

Invite Supplier

Invite Supplier

Invite Supplier

Possible Duplicates

Update Company Details

Terms and Conditions

Available Companies

Select the listing you wish to view or edit.

Video Recommendation

Synterex, Inc.

Products

Member Perk

Perk Permissions

View Permissions:

Claim Permissions:

a Refer-a-Friend Campaign

Projects

Add Image Caption

Add Color

Start a Post

Summary

Select type of event

Featured Video

Send Message

Edit Featured Video

Add new card

Change Featured Content Owner

Send Message

Set New Publish Date

View Email Address

About

Activity

All Users

All Activity

Most Recent

C S

Informed Consent Form of an IND Submission with AgileWriter™

C S

Clinical Study Report and Narratives Initial Draft in Record Time with AgileWriter™

C S

C S

C S

E P

(White Paper) This One’s for the Children: Progress in Pediatric Drug Development in the United States

E P

(White Paper) The Road to Representation in Clinical Research

C B

Pin Activity

Send Message

Share via

Claim Listing

Report a Problem

Select the nature of the problem

Create a Post

Add to Lists